Product Pipeline

IND Code Dosage Form Features Indications Development Development
Locations Stage
TAS-114 Oral dUTPase inhibitor Non-small cell lung cancer (NSCLC) Japan Phase II
US Phase II
Europe Phase II
TAS-115 Oral Multi-kinase inhibitor Prostate cancer Japan Phase II
Idiopathic pulmonary fibrosis Japan Phase II
Osteosarcoma Japan Phase III
TAS-116 Oral HSP90 inhibitor Gastrointestinal stromal tumor (GIST) Japan Filed
Solid tumors US Phase I
Europe Phase I
TAS-117 Oral AKT inhibitor Solid tumors with germline PTEN mutations Japan Phase II
US Phase II
Europe Phase II
TAS-120
 Oral FGFR inhibitor　 Cholangiocarcinoma Japan Phase III
US Phase III
Europe Phase III
Breast cancer US Phase II
Europe Phase II
FGFR aberrations cancer Japan Phase II
US Phase II
Europe Phase II
Urothelial cancer US Phase II
Europe Phase II
TAS0313 Injection Peptide vaccine Urothelial cancer Japan Phase II
TAS3681 Oral 　 Prostate cancer US Phase I
Europe Phase I
TAS0728 Oral 　 Solid tumors US Phase Ⅰ/II
Europe Phase Ⅰ/II
TAS0612 Oral Solid tumors US

Phase Ⅰ
Europe Phase Ⅰ
TAS0953 Oral Solid tumors Japan Phase Ⅰ/II
ET-743 Injection Ovarian cancer Japan Phase Ⅰ
AB122 Injection Solid tumors Japan Phase Ⅰ
Pro-NETU Injection NK1 receptor antagonist Chemotherapy-induced nausea and vomiting (CINV) Japan Filed
TAS-205 Oral PGD synthase inhibitor Duchenne muscular dystrophy(DMD) Japan Phase III
TAS5315 Oral BTK inhibitor Rheumatoid arthritis(RA) Japan Phase II
TAC-302 Oral 　 Detrusor underactivity with overactive bladder Japan Phase II
TAS-303 Oral Selective noradrenalin reuptake inhibitor Stress urinary incontinence Japan Phase II

As of Sep. 30, 2021